Company / Net Income
BridgeBio Oncology Therapeutics, Inc. Net Income History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$7.6M
FY2024
5-year range
-$41.7K / $7.6M
FY2023-FY2024
Trend
+18327.7%
vs FY2023
Sector context
#58 of 216
Health Care
What the data says
At $8M, BridgeBio Oncology Therapeutics, Inc.'s net income ranks #58 of 216 in the Health Care sector.
Based on SEC 10-K filings.
$8M in FY2024.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#58 of 216 in Health CareTop 27% of 216This company $7.6M Sector average $454.1M
▼
-98.3% below sector average
Key checks
Key Insights
- In FY2024, net income increased 18327.7% year-over-year.
- Ranks #58 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $7.6M | +18327.7% |
| FY2023 | -$41.7K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026